Marcio Souza, Praxis Precision Medicines CEO
September 3, 2024 11:23 AM EDTUpdated 04:23 PM
R&D

Prax­is' epilep­sy drug re­duces seizures by 46% in pe­di­atric pa­tients in Phase 2 study

Katherine Lewin

News Reporter

Prax­is Pre­ci­sion Med­i­cines re­leased an­oth­er batch of topline da­ta from its epilep­sy pro­gram on Tues­day, this time from the Phase 2 EM­BOLD study in­ves­ti­gat­ing re­lut­rig­ine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times